Lumos Pharma, Inc. (LUMO) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
August 5, 2021 8:00 AM EDTLumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board
Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress
AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage... More
